Igc Pharma, Inc. ( (IGC) ) has released its Q2 earnings. Here is a breakdown of the information Igc Pharma, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
IGC Pharma, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for Alzheimer’s Disease and related disorders, leveraging Artificial Intelligence (AI) technologies. In its latest earnings report for the quarter ending September 30, 2025, IGC Pharma highlighted its progress in clinical trials and AI integration. The company reported a net loss of $1.8 million for the quarter, with revenues of $191,000, reflecting a decrease from the previous year. Despite the financial loss, IGC Pharma made significant strides in its clinical trials, enrolling over 50% of patients in its ongoing Phase 2 study for its lead therapeutic candidate, IGC-AD1. Additionally, the company is advancing its AI platform to enhance drug discovery and clinical trial design. Looking ahead, IGC Pharma remains focused on advancing its clinical and AI-enabled programs to address unmet medical needs in Alzheimer’s and related disorders, aiming to create value for patients and shareholders.